Analysts Conflicted on These Technology Names: Microsoft (MSFT), Arista Networks (ANET) and Fortinet (FTNT)
Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Microsoft (MSFT – Research Report), Arista Networks (ANET – Research Report) and Fortinet (FTNT – Research Report).
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Microsoft (MSFT)
Barclays analyst Raimo Lenschow maintained a Buy rating on Microsoft today and set a price target of $494.00. The company's shares closed last Friday at $435.28.
According to TipRanks.com, Lenschow is a 3-star analyst with an average return of 1.3% and a 45.2% success rate. Lenschow covers the Technology sector, focusing on stocks such as The Descartes Systems Group, CoreWeave, Inc. Class A, and Klaviyo, Inc. Class A. ;'>
Microsoft has an analyst consensus of Strong Buy, with a price target consensus of $506.31, which is a 17.3% upside from current levels. In a report issued on April 21, Citi also maintained a Buy rating on the stock with a $480.00 price target.
Arista Networks (ANET)
In a report released today, Tim Long from Barclays maintained a Buy rating on Arista Networks, with a price target of $126.00. The company's shares closed last Friday at $91.02.
According to TipRanks.com, Long is a 5-star analyst with an average return of 13.1% and a 61.8% success rate. Long covers the Technology sector, focusing on stocks such as Hewlett Packard Enterprise, Keysight Technologies, and Motorola Solutions. ;'>
Arista Networks has an analyst consensus of Strong Buy, with a price target consensus of $111.17, a 24.8% upside from current levels. In a report issued on May 1, Morgan Stanley also maintained a Buy rating on the stock with a $100.00 price target.
Fortinet (FTNT)
In a report released today, Saket Kalia from Barclays maintained a Hold rating on Fortinet, with a price target of $103.00. The company's shares closed last Friday at $106.18, close to its 52-week high of $114.82.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.2% and a 58.1% success rate. Kalia covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Procore Technologies, and CrowdStrike Holdings. ;'>
Fortinet has an analyst consensus of Moderate Buy, with a price target consensus of $111.55, a 5.5% upside from current levels. In a report issued on April 23, Roth MKM also initiated coverage with a Hold rating on the stock with a $103.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
DELL's CSG Revenues Rise: Is an Improving PC Market the Catalyst?
Dell Technologies DELL AI prospects remain strong, with AI expanding from major cloud service providers to large-scale enterprise deployments and edge computing with PCs. Dell Technologies is a prominent PC maker and is expected to benefit from the recovering demand driven by the PC-refresh cycle. The company is benefiting from the Windows 11 PC refresh cycle as many enterprise customers upgrade to new AI-capable Windows 11 devices, driving strong demand in the commercial segment. In the first quarter of fiscal 2026, CSG revenues were $12.50 billion, up 5% year over year. DELL is also benefiting from an expanding partner base that includes NVIDIA, Microsoft, Meta Platforms and Imbue. In March, Dell Technologies and NVIDIA expanded their AI Factory collaboration, introducing new AI PCs, infrastructure, software, and services to accelerate enterprise AI adoption across various scales. Dell Technologies recently partnered with Lowe's to enhance customer and associate experiences by deploying advanced AI and PC technologies. Using Dell AI Factory with NVIDIA and high-performance Dell devices, Lowe's is optimizing inventory, improving asset protection, and streamlining store operations across its network. In March 2025, Dell Technologies and NVIDIA also expanded their AI Factory collaboration, introducing new AI PCs, infrastructure, software, and services to accelerate enterprise AI adoption across various scales. DELL Faces Stiff Competition in the PC Market Dell Technologies suffers from stiff competition in the PC market from the likes of HP HPQ and Apple AAPL. HPQ is benefiting from a sustained focus on launching new and innovative products. The growing interest in generative artificial intelligence-enabled PCs, along with Windows 11 upgrades and a probable PC refreshment cycle, is likely to drive fresh demand for PCs in 2025. The growing interest in generative AI-enabled PCs might give a fresh boost to HP's PC demand in the years ahead. The company forecasted that 40-60% of all PCs will be AI PCs in the next three years. To make the most of the growing opportunities in this category, HP has launched several AI PCs this year and plans to continue to expand its AI PC portfolio. Apple's Mac business is benefiting from strong demand for M4, M4 Pro, and M4 Max chips. In March 2025, Apple expanded its Mac portfolio with the new MacBook Air powered by the M4 chip with up to 18 hours of battery life and a new 12MP Center Stage camera. DELL's Share Price Performance, Valuation and Estimates DELL's shares have risen 1.1% year to date, underperforming the broader Zacks Computer & Technology sector's return of 1.6%. DELL Stock Performance Image Source: Zacks Investment Research DELL stock is trading at a premium, with a forward 12-month Price/Sales of 0.77X compared with the Computer & Technology sector's 6.36X. DELL has a Value Score of A. DELL Valuation The Zacks Consensus Estimate for second-quarter fiscal 2026 earnings is pegged at $2.26 per share, which has increased 11.5% in the past 30 days. This indicates a year-over-year increase of 19.58%. The consensus mark for fiscal 2026 earnings is pegged at $9.43 per share, which increased 6.91% in the past 30 days. This suggests 15.85% year-over-year growth. DELL currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report HP Inc. (HPQ): Free Stock Analysis Report Dell Technologies Inc. (DELL): Free Stock Analysis Report
Globe and Mail
a day ago
- Globe and Mail
This Nasdaq ETF Could Turn $500 Monthly Into $1 Million
The $1 million mark is a significant financial milestone for many people. There's something about seven figures that feels like you have achieved a real level of financial security. For most people, the most realistic way to reach $1 million is through investing. That's not groundbreaking news, but what is often underappreciated is just how simple it can be. It doesn't take hitting big on a generational winner like Nvidia or Amazon; it can be done with exchange-traded funds (ETFs) that take a lot of the guesswork out of investing. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » One ETF in particular, the Invesco QQQ ETF (NASDAQ: QQQ), has delivered historical returns that could carry you to the $1 million mark. And it's worth considering for your portfolio. An ETF that leans heavily on big tech stocks The Invesco QQQ ETF mirrors the Nasdaq-100, an index that tracks the 100 largest non-financial companies listed on the Nasdaq stock exchange. The ETF is weighted by market cap, so megacap tech stocks make up a large portion of the fund. Below are its top 10 holdings (as of June 13): Microsoft: 8.79% Nvidia: 8.62% Apple:7.34% Amazon: 5.59% Broadcom: 4.80% Meta Platforms:3.72% Netflix:3.17% Tesla: 2.94% Costco Wholesale: 2.69% Alphabet (Class A): 2.54% Having half of a 100-stock ETF in 10 stocks doesn't scream diversification, but it does give you exposure to some of the stock market's heavy hitters. Each of the 10 stocks has considerably outperformed the S&P 500 over the past decade and operates in industries with plenty of growth opportunities. NVDA data by YCharts; ANN = compound annual growth over previous 10 years. This ETF has a history of impressive returns Since it hit the stock market in March 1999, this ETF has averaged around 10% total returns (close to the S&P 500 long-term average). Over the past decade, its returns have been much greater. QQQ data by YCharts. Averaging 17% to 18% annually is impressive, no doubt, but it shouldn't be the long-term expectation. Would it be nice? Absolutely. However, it's much better to plan for more-modest returns and be pleasantly surprised if it does work out that way. For the sake of illustration, let's assume the ETF's returns are in the middle, around 14% annually. Here's how much $500 monthly investments would grow to in different numbers of years. Years Investment Value 15 $258,700 20 $533,400 25 $1.05 million 30 $2.05 million 35 $3.96 million Table by author. Investment values are rounded down to the nearest hundred and take into account the ETF's 0.20% expense ratio. The biggest factor is time because that's what allows compound earnings to work their true magic. Even if we use the more conservative 10% annual returns, you could hit the $1 million mark a little after 30 years. In all fairness, these are assumptions, and we should never take past performance as a guarantee of future results. However, it does show this ETF's long-term potential with consistent investments over time. Use this ETF as a supplemental part of your portfolio Although this ETF is full of world-class companies and has all the tools to outperform the market, I wouldn't make it a large portion of my portfolio because of how concentrated it is. The tech sector is over 57% of the ETF, so your returns will depend a lot on the sector's performance, especially the " Magnificent Seven" companies. Granted, the tech sector has been the highest-performing over the past decade or so, but there's a risk that comes with relying heavily on one sector. It's especially important to be aware of how concentrated your stock portfolio is if you're investing in the S&P 500, which has become tech-heavy over the past few years with the explosion of megacap tech stocks. Even if you can't afford to dedicate $500 monthly solely to this ETF, a relatively small amount can go a long way over time. Should you invest $1,000 in Invesco QQQ Trust right now? Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Stefon Walters has positions in Apple and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Costco Wholesale, Meta Platforms, Microsoft, Netflix, Nvidia, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
a day ago
- Globe and Mail
The Smart Money Is Moving Toward AI Healthcare Tools That Actually Touch Patients
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – AI is rapidly infiltrating every corner of the healthcare system, but so far, ambient scribes have taken the lead as the most visible breakthrough. As adoption broadens, experts are now evaluating which tools offer real ROI—and how quickly early adopters could benefit. Clinician workloads are already shrinking thanks to voice AI, while hospitals are deploying intelligent agents to streamline operations and boost care quality. For investors still hunting early-stage opportunities in this space, several publicly traded names are showing fresh momentum, including Avant Technologies, Inc. (OTCQB: AVAI), NVIDIA Corporation (NASDAQ: NVDA), Novo Nordisk A/S (NYSE: NVO), Alphabet, Inc. (NASDAQ: GOOG, GOOGL), and Microsoft Corporation (NASDAQ: MSFT). Private-market momentum is heating up fast, with venture capital pouring into AI-driven healthcare startups. In the first quarter alone, AI companies secured over half of all digital health funding—underscoring the sector's growing appeal. Notable rounds include $45 million for Ellipsis Health and $28 million for Autonomize AI, both focused on reshaping clinical decision-making. From early diagnostics to advanced drug discovery, the pace of innovation is picking up—and retail investors are starting to take notice. One example is the rollout of AI-powered screenings for diabetic retinopathy now underway across Costa Rica, Nicaragua, and Panama. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The fast, non-invasive test detects early retinal changes—often before symptoms appear—and delivers secure results within minutes. By embedding the service in retail pharmacies and preparing for a parallel launch in Mexico, the partners are bringing care closer to patients while generating real-world data to support broader commercialization. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." The rollout also gives Avant a timely proof point as it moves to consolidate Vision AI under one roof. Earlier this month, the company signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners. While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff. Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module —pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company. On the financial side, the planned merger would fold all outstanding Ainnova shares into Avant's public float, avoiding cash dilution and fully aligning the combined team's incentives. Management says any future fund-raising would be aimed at three priorities: completing the automated camera, widening pharmacy deployments, and supporting U.S. regulatory milestones. Taken together, the pharmacy roll-out, planned Ainnova acquisition, and imminent camera launch signal a turning point for Avant. What began as an AI incubator is fast becoming a full-stack diagnostics company, complete with proprietary hardware, an expanding library of predictive algorithms, and retail-level distribution partners. If execution matches vision, Vision AI could cut referral delays, open earlier treatment windows, and give resource-strained health systems specialist-grade insight at primary-care prices—turning headline-grabbing tech into tangible patient benefits. NVIDIA Corporation (NASDAQ: NVDA) and Novo Nordisk A/S (NYSE: NVO) are joining forces to advance drug discovery using AI models trained on the NVIDIA DGX Cloud platform. The partnership is supported by Denmark's DCAI supercomputing center and aims to improve early-stage research for identifying drug targets and molecules. 'AI is essential for every industry, and there's no other field that will benefit more from acceleration than drug discovery,' said Rory Kelleher, senior director of business development for life sciences at NVIDIA. 'Working with Novo Nordisk, we're advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development.' Novo Nordisk will adopt NVIDIA's BioNeMo platform to build customized generative AI tools using its proprietary biological data. 'By coupling NVIDIA's accelerated computing platform and expertise with Novo's deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,' said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk. 'Gefion will allow us to run experiments at an unprecedented scale.' DCAI views this collaboration as a model for how public supercomputing resources can unlock innovation in life sciences. For investors, the alliance highlights a rising trend of AI infrastructure enabling breakthroughs in biopharma. Alphabet, Inc. (NASDAQ: GOOG, GOOGL) subsidiary Google, through its DeepMind division, has introduced Med-Gemma, a new generative AI model optimized for healthcare developers building diagnostic and imaging apps. The tool aims to streamline early-stage development by offering pretrained models trained on expansive medical imaging datasets. Med-Gemma joins other Google health-focused initiatives like Med-PaLM 2 and AMIE, signaling a coordinated strategy toward AI-native clinical applications. The company continues to expand its AI footprint across healthcare with open-access tools designed to catalyze innovation at scale. Microsoft Corporation (NASDAQ: MSFT) is advancing healthcare AI innovation through strategic initiatives presented at HLTH Europe 2025, emphasizing breakthroughs in diagnostics and precision medicine via collaborations like its Mayo Clinic partnership. A central feature was Dragon Copilot, a generative AI tool designed to streamline documentation and enhance clinician-patient engagement across Europe. Microsoft also addressed growing global health disparities by promoting equitable, inclusive solutions rooted in responsible AI practices. These efforts reflect Microsoft's goal of enabling healthier outcomes for patients and providers worldwide. Source: CONTACT: cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
